Eli Lilly has filed a new migraine drug, lasmiditan, with the US regulator, the first drug in its class to be reviewed as a treatment for the condition.
The FDA has approved Eli Lilly’s Emgality (galcanezumab) for migraine prevention in adults, the third in a group of new class of drugs for the condition.
The FDA has finally approved Teva’s potential blockbuster migraine drug Ajovy after months of delays due to concerns about the manufacturing plant operated by the company’s partner, Celltri
A group of pharma companies – Amgen, AstraZeneca and GlaxoSmithKline – have partnered with the UK government’s Equalities Office and Women’s Business Council to support small businesses in